...
首页> 外文期刊>HNO >Therapy of recurrent and metastatic squamous cell carcinoma of the head and neck: Highlights of the ASCO Meeting 2013 [Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013]
【24h】

Therapy of recurrent and metastatic squamous cell carcinoma of the head and neck: Highlights of the ASCO Meeting 2013 [Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013]

机译:头颈部复发性和转移性鳞状细胞癌的治疗:2013年ASCO会议的重点

获取原文
获取原文并翻译 | 示例

摘要

In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.
机译:最初诊断时,在许多情况下,头颈部鳞状细胞癌已经处于晚期。尽管进行了明确的治疗,局部区域复发和转移仍很普遍,患者最终需要全身治疗。表皮生长因子受体(EGFR)抑制剂已被证明可以显着延长生存期,因此除铂和5-FU治疗外,已成为头颈部复发和转移性鳞状细胞癌的一线治疗。在以铂为基础的治疗失败的情况下,EGFR抑制剂的治疗效果也良好。目前正在研究进一步的策略,例如挽救手术,基于铂的化学疗法,靶向治疗,化学放疗和再照射,以减少毒性并改善生存率和与健康相关的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号